低分子肝素治疗小儿肾病综合征的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the Clinical efficacy of low molecular heparin in children with nephrotic syndrome.Methods100 children with nephrotic syndrome admitted to our hospital from February 2013 to February 2017 were selected and were divided into the observation group and the control group according to the method of lottery,with 50 cases in each group.Patients in the control group were given conventional therapy and prednisone while the observation group were given low molecular heparin on the basis of the control group.The levels of Cer,BUN,SCr,24 h urine protein, Alb and TC,PT,APTT and the incidence of adverse events were compared between two groups.ResultsThe levels of Cer,BUN,SCr,24 h urine protein and TC of patients in the observation group were lower than those in the control group; the level of Alb was higher than that in the control group;the PT and APTT were shorter than those in the control group;the incidence of adverse events was lower than that in the incidence of adverse events,and all the differences were statistically significant(P＜0.05).ConclusionLow molecular heparin in the treatment of children with nephrotic syndrome is effective and safe.

Key words： Low molecular heparin Children Nephrotic syndrome Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Ting
	ZHONG Liang
	LI Hao-hua
	YANG Wei-si
	XU Bai-hua

Cite this article:

HU Ting,ZHONG Liang,LI Hao-hua, et al. Clinical efficacy of low molecular heparin in children with nephrotic syndrome[J]. 中国当代医药, 2017, 24(13): 112-114.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I13/112

[1]	但刚，刘媛，江忠勇.低分子肝素治疗肾病综合征患儿高凝状态的实验室观察[J].重庆医学，2015，78（14）：1916-1917.
[2]	Rodgers AL，Allie-Hamdulay S，Jackson GE，et al.Theoretical modeling of the urinary supersaturation of calcium salts in healthy individuals and kidney stone patients：precursors，speciation and therapeutic protocols for decreasing its value[J].J Cryst Growth，2013，382（3）：67-74.
[3]	魏乐群.低分子肝素在小儿肾病综合征中的应用研究[J].河南科技大学学报（医学版），2014，32（1）：41-42.
[4]	周平，谭忠友，秦弦.小儿肾病综合征应用低分子肝素联合泼尼松治疗的临床效果[J].检验医学与临床，2016，13 （19）：2810-2812.
[5]	邓洪.低分子肝素联合卡托普利治疗肾病综合征的疗效分析[J].当代医学，2012，18（20）：25.
[6]	余韩波，林俊川，胡晓辉.低分子肝素联合卡托普利治疗肾病综合征的临床疗效分析[J].中国实用医药，2014，47 （18）：9-11.
[7]	Moussata J，Wang Z，Wang J.Development and validation of an HPLC method for the simultaneous quantification of indole-3-carbinol acetate，indole-3-carbinol，and 3，3′-diindolylmethane in mouse plasma，liver，and kidney tissues[J].J Chromatogr B Analyt Technol Biomed Life Sci，2014，958：1-9.
[8]	吴乾东.低分子肝素治疗小儿肾病综合征疗效观察[J].饮食保健，2016，3（16）：23.
[9]	刘敏.低分子肝素和泼尼松用于肾病综合征患儿治疗中的临床效果[J].中外女性健康研究，2016，（14）：31，37.
[10]	宋香平.低分子肝素辅助治疗小儿肾病综合征的临床效果观察[J].世界临床医学，2016，10（8）：158.
[11]	谭蔚越.联用低分子肝素和卡托普利治疗肾病综合征的效果评析[J].当代医药论丛，2016，14（7）：110-111.
[12]	闫灵芝.肾病综合征治疗中应用低分子肝素的疗效分析[J].中国现代药物应用，2016，14（4）：168-169.
[13]	萨初然贵.32例低分子肝素治疗小儿肾病综合征的临床分析[J].医药前沿，2014，74（16）：132.
[14]	郑立平，李润娥，武超，等.低分子肝素联合注射用甲泼尼龙琥珀酸钠治疗肾病综合征的药学监护[J].临床合理用药杂志，2015，96（22）：62-63.
[15]	万婕.卡托普利联合低分子肝素治疗肾病综合征的临床疗效分析[J].中外女性健康研究，2015，（9）：227.